Get the Stockscreener App
0.7083
2.65%
0.0183
Pre-market:
.68
-0.0283
-4.00%
Hoth Therapeutics Inc stock is traded at $0.7083, with a volume of 482.10K.
It is up +2.65% in the last 24 hours and down -12.54% over the past month.
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA). Its current assets are focused in treating cancer, skin toxicities, Alzheimer's, and weight loss.
See More
Previous Close:
$0.69
Open:
$0.69
24h Volume:
482.10K
Relative Volume:
0.22
Market Cap:
$13.55M
Revenue:
-
Net Income/Loss:
$-12.47M
P/E Ratio:
-0.7774
EPS:
-0.9111
Net Cash Flow:
$-10.10M
1W Performance:
+18.05%
1M Performance:
-12.54%
6M Performance:
-40.97%
1Y Performance:
-17.06%
1-Day Range:
$0.67
$0.7149
1-Week Range:
$0.5693
$0.7149
52-Week Range:
$0.4894
$2.115
Hoth Therapeutics Inc Stock (HOTH) Company Profile
Name
Hoth Therapeutics Inc
Sector
Industry
Phone
(646)756-2997
Address
720 MONROE STREET, HOBOKEN, NY
Compare HOTH vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HOTH
Hoth Therapeutics Inc
|
0.7083 | 13.20M | 0 | -12.47M | -10.10M | -0.9111 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Hoth Therapeutics Inc Stock (HOTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-15-19 | Initiated | The Benchmark Company | Speculative Buy |
Hoth Therapeutics Inc Stock (HOTH) Latest News
HOTH Receives Patent Allowance for HT-KIT Therapeutic Developmen - GuruFocus
Hoth Therapeutics Awarded U.S. Patent for Cancer-Fighting HT-KIT Oncology Platform - PR Newswire
Hoth Therapeutics shares slide after shift toward AI semiconductor strategy (HOTH) - MSN
HOTH Should I Buy - Intellectia AI
Hoth Therapeutics (NASDAQ: HOTH) pivots to AI semiconductor infrastructure as Rocket One - Stock Titan
Hoth Therapeutics to rebrand as Rocket One, enter AI chips By Investing.com - Investing.com South Africa
Hoth Therapeutics to rebrand as Rocket One, enter AI chips - Investing.com UK
Exclusive: Hoth Therapeutics to rebrand to pursue AI chip technologies - MSN
Hoth Therapeutics stock tumbles on business pivot to AI chips By Investing.com - Investing.com South Africa
Hoth Therapeutics Inc to change name to Rocket One and restructure for AI semiconductor focus - marketscreener.com
Hoth Therapeutics Inc To Change Name To Rocket One And Restructure For Ai Semiconductor Focus - TradingView
Hoth Therapeutics stock tumbles on business pivot to AI chips - Investing.com
Hoth Therapeutics Restructures as Rocket One - Moomoo
AI Chip Energy Efficiency: Hoth Therapeutics Restructures as Rocket One Inc. to Enter the AI Semiconductor Infrastructure Market with Acquisition of Exclusive Rights to Next Generation AI Semiconductor Acceleration Technology Built on Non-Volatile Nanoma - marketscreener.com
Press Release: AI Chip Energy Efficiency: Hoth Therapeutics Restructures as Rocket One Inc. to Enter the AI Semiconductor Infrastructure Market With Acquisition of Exclusive Rights to Next Generation AI Semiconductor Acceleration Technology Built on... - Moomoo
EXCLUSIVE: Hoth Therapeutics To Rebrand To Pursue AI Chip Technologies - Yahoo Finance
Hoth Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Hoth Therapeutics (NASDAQ: HOTH) Q1 loss deepens going-concern risk despite new funding - Stock Titan
HOTH.O - Reuters
TradingKey - TradingKey
Hoth Therapeutics stock (US44133K1097): Spain greenlights Phase 2a trial for HT-001 in cancer skin t - AD HOC NEWS
Hoth Therapeutics Launches Rocket One Space Subsidiary Initiative - TipRanks
Hoth Therapeutics (NASDAQ: HOTH) creates Rocket One for space assets - Stock Titan
Hoth Therapeutics Receives Nasdaq Minimum Bid Price Deficiency Notice - The Globe and Mail
Hoth Therapeutics secures European authorization in Spain - marketscreener.com
Hoth Therapeutics Secures European Authorization In Spain - TradingView
Hoth Therapeutics secures Spain approval for phase 2a trial - Investing.com
Hoth Therapeutics secures Spain approval for phase 2a trial By Investing.com - Investing.com Australia
Hoth Therapeutics Secures European Authorization in Spain for HT-001 Phase 2a Trial as Interim Data Show Strong Efficacy in Cancer Patients - The AI Journal
Cancer patients stayed on treatment as Hoth trial eased rash - Stock Titan
Hoth Therapeutics Receives Nasdaq Delisting Notice for Non-Compliance With Minimum Bid Price Rule - Minichart
Hoth Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Hoth Therapeutics (HOTH) faces Nasdaq $1 bid-price deficiency and delisting risk - Stock Titan
Why is HOTH stock up 70% after-hours today? - MSN
Exclusive: Hoth Therapeutics targets faster drug discovery with new AI platform - MSN
HOTH Technical Analysis | Trend, Signals & Chart Patterns | HOTH THERAPEUTICS INC (NASDAQ:HOTH) - ChartMill
HOTH Hoth Therapeutics Inc. posts wider than expected Q4 2025 loss even as shares climb nearly 8 percent in today's trading.Decline Risk - Cổng thông tin điện tử tỉnh Tây Ninh
Hoth Therapeutics Inc Stock (HOTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):